Renalytix PLC - London-based diagnostics company focused on kidney health - Completes a $8.8 million equity subscription and a $21.2 million subscription for convertible bonds. Company raises $26.8 million as a result. Proceeds will be used for general working capital purposes and to support company growth.

Chair Christopher Mills subscribed for a total of 551,724 shares at $3.625 each. Mills now holds 13.0% of the company’s share capital.

Directors Ann Berman and Timothy Scannell now hold 0.05% and 0.09% of the company’s share capital, respectively, as a result of their subscriptions. President Thomas McLain holds 0.08% following his subscription.

Current stock price: 235.00 pence, down 2.1% in London

12-month change: down 75%

Copyright 2022 Alliance News Limited. All Rights Reserved.